Ali Murat SEDEF, Fatih KÖSE, Ahmet Taner SÜMBÜL, Hüseyin MERTSOYLU, Ali Ayberk BESEN, Ahmet SEZER, Özgür ÖZYILKAN, Hüseyin ABALI

Nöroendokrin tümörlerin klinikohistopatolojik özellikleri ve tedavi sonuçları: tek merkez deneyimi

Amaç: Nöroendokrin tümörler (NET) tümör ve hasta özellikleri, muhtemelen tüm dünyada çevresel ve genetik faktörlerin yol açtığı coğrafi alanlar arasında önemli değişiklik göstermektedir. Bu nedenle, tek merkez deneyimi bildirmek, epidemiyolojik görüşleri açıklığa kavuşturmaya ve karar verme sürecini geliştirmeye yardımcı olabilirGereç ve Yöntem: Başkent Üniversitesi Tıbbi Onkoloji Anabilim Dalına başvuran ve takip edilen, tümör özelliklerini, tedavi yöntemlerini, sağkalım oranlarını ve prognostik faktörlerini kaydettiğimiz 82 NET tanılı hastanın retrospektif analizi yapılmıştır.Bulgular: Tüm grup ve lokal evredeki NET'lerin genel sağkalım süresi, sırasıyla 44 ve 24 aydır. En sık görülen primer tümör alanı gastrointestinal sistem ve daha sonra pankreas bölgesi olarak bulundu. Küratif cerrahi rezeksiyon oranı karsinoid sendrom ile başvuran hastaların%46'sında ve %8.5'inde idi. Karaciğer metastazı akciğer, kemik ve lenf nodu metastazı ile karşılaştırıldığında en yaygın metastatik bölge idi. Hastaların %70'inden fazlası kemoterapi ve somatostatin analoğu ile tedavi edildi. Sonuç: Daha yüksek greydli, erkek cinsiyeti olan ve ileri yaşta (>65 yaş) hastalarda sağkalım oranı düşüktür. Bununla birlikte, nispeten düşük hasta sayısı ve yeni tedavi yöntemlerinin (<%10) daha az kullanımı, çalışmamızın gelecek için yönermeler üretebilmesi için sınırlamalar getirdi.

Anahtar Kelimeler:

nöroendokrin, tümör, sonuçlar

Clinicohistopathological features and treatment outcomes of neuroendocrine tumors: a single center experience

Purpose: Tumor and patient characteristics of neuroendocrine tumors (NET) significantly change between geographical locations that probably induced by environmental and genetic factors throughout the world. Therefore, reporting single center experience may help clarifying epidemiological view and improving decision-making process. Materials and Methods: We performed retrospective analysis of 115 patients of NETs those who followed by Baskent University, department of Medical Oncology and department of General Surgery to record patients and tumors characteristics, treatment modalities, survival rates, and prognostic factors. Results: Median overall survival (OS) time for all group and localized NETs were 44 and 24 months, respectively. Most common primary site was found as gastrointestinal system and then pancreatic region. Curative surgical resection rate was 46% and 8.5% of patients presented with carcinoid syndrome. Liver metastasis was far the most common metastatic site compared to lung, bone, and lymph node metastasis. Over 70 percent of patients were treated with chemotherapy and somatostatin analogs. Conclusion: Patients with higher grade, male gender, and advanced age (>65 years old) had poor survival rate. However, relatively low number of patients and less usage of (<10%) of new treatment modalities created limitations for producing future directions from our study.

Keywords:

Neuroendocrine Tumors, Outcomes,

PDF

___

1. Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33:1855-63.
2. Öberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30 (Suppl 1):3–7.
3. Dogan M, Yalcin B, Ozdemir NY, Arslan UY, Dogan L, Utkan G et al...Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature. Med Oncol. 2012;29:2021–26.
4. Liu Y, Sturgis CD, Grzybicki DM, Jasnosz KM, Olson PR, Tong M et al. Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma. Mod Pathol. 2001;14:880–5.
5. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am., 2011;40:1–18.
6. Moertel CG. Karnofsky memorial lecture: An odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502-22.
7. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511.
8. Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008;2:113-25.
9. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AKC et al. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer. 2008;113:2655–64.
10. Yucel B, Babacan NA, Kacan T, Eren AA, Eren MF, Bahar S et al. Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pac J Cancer Prev. 2013;14:6687–92.
11. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240:117-22.
12. Yao W., Wang W. and Li G. Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases. Zhonghua Zhong Liu Za Zhi. 2014;36:287-93.
13. K. Öberg, P. Hellman, P. Ferolla& M. Papotti. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 (Supplement 7):vii120–3.
14. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72.
15. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010;145:276–80.